RxDoctor Payments Data

Anthony Cirino, DO

Ophthalmology · Brunswick, OHNPI 1588629976

Payments from drug & device makers

$2,243in general payments, 2019–2025

Across 125 payments — averaging $17.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$398
  • Alcon$274
  • AbbVie$243
  • Sun Pharmaceutical Industries Inc.$221
  • Novartis$200
  • Oyster Point Pharma, Inc.$170
  • plus $737 from 11 others

What the payments were for

  • Food & beverage$2,22599%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,243 in reported general payments places this provider in the 60th percentile of 640 ophthalmology providers in Ohio.

See all ophthalmology providers in Ohio

Medicare billing

Part B allowed, 2024
$193,379
Medicare patients
762
Services billed
1,936

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine103$104,744
XiidraLifitegrast41$63,147
LumiganBimatoprost67$36,946
VyzultaLatanoprostene Bunod74$26,485
Cyclosporine26$24,326
MieboPerfluorohexyloctane/Pf27$23,343
TyrvayaVarenicline Tartrate23$14,990
RhopressaNetarsudil Mesylate39$12,342
AlrexLoteprednol Etabonate20$10,914
BesivanceBesifloxacin Hcl50$10,732
Lotemax SmLoteprednol Etabonate38$9,948
SimbrinzaBrinzolamide/Brimonidine Tart33$7,698
RocklatanNetarsudil Mesylat/Latanoprost17$6,422
Latanoprost317$4,184
ProlensaBromfenac Sodium11$3,606

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$243$141,690170 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo$398$112,975142 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCAlrex, Besivance, Lotemax Sm, Prolensa$164$35,200119 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$16$18,76456 claims
Oyster Point Pharma, Inc.Tyrvaya$170$14,99023 claims
AlconSimbrinza$274$7,69833 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 640 ophthalmology providers in Ohio.

Other ophthalmology in Brunswick

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →